This site is intended for Healthcare professionals only.

Antithrombotic therapy in atrial fibrillation-Updated CHEST Guidelines


Antithrombotic therapy in atrial fibrillation-Updated CHEST Guidelines

The American College of Chest Physicians has announced updates to the evidence-based guidelines on antithrombotic therapy for atrial fibrillation. The guidelines have been published in the journal CHEST.

Atrial fibrillation is one of the most common forms of cardiac arrhythmia with an increase in prevalence and incidence with age. In adults over the age of 40, there is a one in four lifetime risk of developing atrial fibrillation.

The updated guidelines reflect the most up-to-date clinical research since the last publication in 2012 according to the Expert Panel.

Key recommendations and shifts from previous guidelines include:

  • For patients with atrial fibrillation without valvular heart disease, including those with paroxysmal atrial fibrillation who are at low risk of stroke (eg, CHA2DS2VASc score of 0 in males or 1 in females), we suggest no antithrombotic therapy.
  • For patients with a single non-sex CHA2DS2VASc stroke risk factor, we suggest oral anticoagulation rather than no therapy, aspirin or combination therapy with aspirin and clopidogrel.
  • For those at high risk of stroke, we recommend oral anticoagulation rather than no therapy, aspirin or combination therapy with aspirin and clopidogrel.
  • Where we recommend or suggest in favour of oral anticoagulation, we suggest using a novel oral anticoagulant (NOAC) rather than adjusted-dose vitamin K antagonist therapy. With the latter, it is important to aim for good quality anticoagulation control with a time in therapeutic range (TTR) >70%.
  • Attention to modifiable bleeding risk factors should be made at each patient contact, and a HAS-BLED score should be used to assess the risk of bleeding where high-risk patients (>=3) can be identified for earlier review and follow-up visits.

“Understanding the most up-to-date clinical research assists medical professionals in providing the best quality of care for their patients,” says President of the CHEST Foundation Lisa K. Moores, MD, FCCP, and a member of CHEST’s Guidelines Oversight Committee. “It is essential that these guidelines are shared with medical professionals and understood by their patients as well.”

For full guidelines log on to :

DOI: https://doi.org/10.1016/j.chest.2018.07.040

The following two tabs change content below.
Dr. Kamal Kant Kohli

Dr. Kamal Kant Kohli

A Medical practitioner with a flair for writing medical articles, Dr Kamal Kant Kohli joined Medical Dialogues as an Editor-in-Chief for the Speciality Medical Dialogues. Before Joining Medical Dialogues, he has served as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils of India. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751
Source: With inputs from CHEST

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted